Clarius Group LLC Reduces Stake in Lyell Immunopharma, Inc. $LYEL

Key Points

• Clarius Group LLC significantly reduced its stake in Lyell Immunopharma by 95.2% during the second quarter, now holding only 19,138 shares valued at approximately $169,000.
• In contrast, other hedge funds like AQR Capital Management LLC and Acadian Asset Management LLC increased their positions in the company by 773.5% and 204.2%, respectively, illustrating mixed confidence among institutional investors.
• Analysts have issued a consensus rating of "Sell" for Lyell Immunopharma, with a target price of $15.00 despite recent revenue exceeding expectations, indicating cautious sentiment towards the company's performance.

Clarius Group LLC reduced its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 95.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,138 shares of the company's stock after selling 380,030 shares during the period. Clarius Group LLC owned about 0.13% of Lyell Immunopharma worth $169,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of LYEL. Exchange Traded Concepts LLC increased its position in Lyell Immunopharma by 82.4% during the first quarter. Exchange Traded Concepts LLC now owns 246,349 shares of the company's stock worth $133,000 after buying an additional 111,299 shares in the last quarter. AQR Capital Management LLC increased its position in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock worth $94,000 after buying an additional 154,327 shares in the last quarter. Acadian Asset Management LLC increased its position in Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares in the last quarter. Nuveen LLC purchased a new position in Lyell Immunopharma during the first quarter worth $345,000. Finally, Almitas Capital LLC increased its position in Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after buying an additional 1,432,086 shares in the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LYEL has been the subject of several recent research reports. HC Wainwright reissued a "neutral" rating and set a $10.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, June 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Lyell Immunopharma in a research report on Saturday, September 27th. Finally, Wall Street Zen upgraded Lyell Immunopharma from a "sell" rating to a "hold" rating in a report on Monday, September 1st. One investment analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Sell" and a consensus target price of $15.00.

Lyell Immunopharma Stock Down 0.9%

LYEL stock opened at $17.69 on Wednesday. Lyell Immunopharma, Inc. has a 52-week low of $7.65 and a 52-week high of $30.00. The stock's fifty day simple moving average is $12.47 and its 200-day simple moving average is $10.50. The stock has a market capitalization of $339.82 million, a price-to-earnings ratio of -0.73 and a beta of -0.07.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.80) by $0.91. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. As a group, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.